End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.8 SEK | -0.23% | -0.90% | +31.14% |
Apr. 22 | EQL Pharma AB Announces Mellozzan Launched in Germany and Austria | CI |
Feb. 13 | EQL Pharma AB Provides Sales Guidance for the Year 2023/24 | CI |
Sales 2024 * | 363M 33.46M | Sales 2025 * | 425M 39.15M | Capitalization | 1.27B 117M |
---|---|---|---|---|---|
Net income 2024 * | 60M 5.53M | Net income 2025 * | 76M 7.01M | EV / Sales 2024 * | 3.62 x |
Net Debt 2024 * | 41M 3.78M | Net cash position 2025 * | 5M 461K | EV / Sales 2025 * | 2.99 x |
P/E ratio 2024 * |
21.2
x | P/E ratio 2025 * |
16.7
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
1 day | -0.23% | ||
1 week | -0.90% | ||
Current month | +0.92% | ||
1 month | +0.46% | ||
3 months | +21.67% | ||
6 months | +55.87% | ||
Current year | +31.14% |
Managers | Title | Age | Since |
---|---|---|---|
Axel Schörling
CEO | Chief Executive Officer | 38 | 18-01-31 |
Founder | 59 | 05-12-31 | |
Anna Jönsson
DFI | Director of Finance/CFO | 40 | 21-12-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 59 | 05-12-31 | |
Director/Board Member | 64 | 14-12-31 | |
Director/Board Member | 51 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 43.8 | -0.23% | 1,090 |
24-05-07 | 43.9 | -0.68% | 1,996 |
24-05-06 | 44.2 | -1.34% | 6,061 |
24-05-03 | 44.8 | +1.36% | 6,644 |
24-05-02 | 44.2 | +1.84% | 13,365 |
End-of-day quote NORDIC GROWTH MARKET, May 07, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+31.14% | 117M | |
-33.93% | 14.88B | |
-24.94% | 12.18B | |
+16.46% | 6.53B | |
-25.71% | 6.52B | |
-8.01% | 6.06B | |
-2.34% | 4.64B | |
+60.00% | 4.59B | |
-8.19% | 3.61B | |
-6.77% | 3.06B |
- Stock Market
- Equities
- EQL Stock